Skip to main content
NTLA $9.70 -8.06%
NTLA logo
NTLA · Intellia Therapeutics, Inc.
Track NTLA — free
$9.70 -0.85 (-8.06%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
Market Cap
$1.36B
Shares
140.36M
Volume · Nov 13 11.42M Avg daily vol (3M) 4.57M
All webcasts

Earnings call · FY2026 Q3

Intellia Therapeutics, Inc. (NTLA) Q3 2026 Earnings Call

Concluded Nov 5, 2026
Nov 5, 2026
Period
FY2026 Q3
Runtime
—
Sources
3 artifacts
Revenue $7.16M -48% YoY
Diluted EPS -$0.91
Net income -$127.48M
Open full screen Slides 74 8-K 10-Q

Executive readout · one minute

What the filings say

10-Q report · filed Nov 5, 2026
Intellia Therapeutics said the FDA accepted lonvo-z’s BLA, granted Priority Review and set a March 10, 2027 target action date, supporting a planned first quarter 2027 U.S. launch if approved.

The audio replay and transcript follow the call.

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document